CJC-1295 and ipamorelin are not alternatives — they act on different receptor systems. Understanding why they are studied together requires understanding what each does alone.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | CJC-1295 | Ipamorelin |
|---|---|---|
| Receptor | GHRH receptor (GHRHR) | Ghrelin receptor (GHS-R1a) |
| Pathway | cAMP / PKA cascade in somatotrophs | IP₃ / Ca²⁺ cascade in somatotrophs |
| Natural ligand | GHRH (hypothalamic pulse) | Ghrelin (gut-derived, pulsatile) |
| Chain length | 30 AA (no DAC) / 30 AA + DAC | 5 AA (pentapeptide) |
| Half-life | ~30 min (no DAC) / ~6–8 days (DAC) | ~2 h |
| GH release pattern | Pulsatile (no DAC) / Sustained (DAC) | Pulsatile |
| Cortisol / ACTH effect | Minimal | Minimal (key selectivity feature) |
| Prolactin effect | Minimal | Minimal |
| FDA approval | None | None |
| WADA status | Prohibited (S2) | Prohibited (S2) |
Pituitary somatotrophs — the cells that synthesize and secrete GH — carry receptor sites for both GHRH and ghrelin. CJC-1295 occupies the GHRH receptor (a cAMP/PKA signal) while ipamorelin occupies the ghrelin receptor (an IP₃/Ca²⁺ signal). When both arrive at the same somatotroph simultaneously, the two intracellular cascades amplify each other, producing a combined GH pulse substantially larger than additive.
That synergy is the primary rationale for studying the pair as a combination rather than individually — each contributes a distinct, convergent signal.
The DAC (Drug Affinity Complex) addition extends CJC-1295’s half-life from ~30 minutes to ~6–8 days by allowing covalent binding to serum albumin. No-DAC produces brief, pulsatile GH pulses compatible with natural rhythm; DAC produces sustained GH/IGF-1 elevation but blunts pulsatility.
Ipamorelin’s distinguishing feature among GHRPs is selectivity: earlier GHRPs (GHRP-6, hexarelin) release GH alongside ACTH, cortisol, and prolactin, whereas ipamorelin activates GHS-R1a with high selectivity — the main reason it is the most widely used GHRP in combination research.
These are complements, not competitors: different receptors converging on the same somatotroph, studied together for a synergistic GH pulse. Both have receptor-binding and GH-release characterization plus some human PK/PD data (stronger for CJC-1295); endpoints like body composition rest on thinner, smaller-trial evidence. Neither is FDA-approved, and both are WADA-prohibited (S2).
They act on entirely different receptors. CJC-1295 (a GHRH analog) binds the GHRH receptor via a cAMP/PKA cascade. Ipamorelin (a GHRP) binds the ghrelin receptor (GHS-R1a) via an IP₃/Ca²⁺ cascade. Because the two pathways converge downstream on the same pituitary somatotroph, combining them produces synergistically larger GH pulses than either alone.
When a GHRH-receptor signal (CJC-1295) and a ghrelin-receptor signal (ipamorelin) arrive at the same pituitary somatotroph simultaneously, the two intracellular cascades amplify each other. The combined GH pulse is substantially larger than additive. This synergy is the primary rationale for studying them as a combination.
The DAC addition extends half-life from ~30 minutes (no DAC) to ~6–8 days (DAC) via covalent binding to serum albumin. No-DAC produces brief, pulsatile GH pulses compatible with natural GH rhythm; DAC produces sustained GH and IGF-1 elevation but blunts pulsatility. The choice depends on whether pulsatile or sustained exposure is the endpoint of interest.
Earlier GHRPs (GHRP-6, hexarelin) release GH alongside ACTH, cortisol, and prolactin. Ipamorelin activates GHS-R1a with high selectivity, releasing GH without meaningfully raising the others — the primary reason it is the most widely used GHRP in combination research.
No. Neither compound is FDA-approved. Both are prohibited by the World Anti-Doping Agency under category S2 (Peptide Hormones). The only currently approved GH-axis peptide in this catalog is tesamorelin (Egrifta), for a specific HIV-related indication.
Both have pharmacological characterization data (receptor binding, GH release curves) and some human PK/PD data — peer-reviewed human PK exists for CJC-1295. Evidence for specific endpoints like body composition is thinner, mostly from small trials or case series. Neither has completed Phase 3 trials.